CTNNA2 and neoplasm: Studies have shown that patients with advanced non-small-cell lung cancer who had more tumor antigens were more sensitive to immunotherapy (Rolfo et al., 2017), which suggests that LUAD patients with CTNNA2 mutation may be more likely to benefit from immunotherapy than those without this mutation.